Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 142

1.

Low-molecular-weight heparin in the treatment of patients with venous thromboembolism.

Columbus Investigators, Büller HR, Gent M, Gallus AS, Ginsberg J, Prins MH, Baildon R.

N Engl J Med. 1997 Sep 4;337(10):657-62.

2.

A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. Tinzaparine ou Heparine Standard: Evaluations dans l'Embolie Pulmonaire.

Simonneau G, Sors H, Charbonnier B, Page Y, Laaban JP, Azarian R, Laurent M, Hirsch JL, Ferrari E, Bosson JL, Mottier D, Beau B.

N Engl J Med. 1997 Sep 4;337(10):663-9.

3.

Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis.

Breddin HK, Hach-Wunderle V, Nakov R, Kakkar VV; CORTES Investigators. Clivarin: Assessment of Regression of Thrombosis, Efficacy, and Safety.

N Engl J Med. 2001 Mar 1;344(9):626-31.

5.

A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prévention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group.

Decousus H, Leizorovicz A, Parent F, Page Y, Tardy B, Girard P, Laporte S, Faivre R, Charbonnier B, Barral FG, Huet Y, Simonneau G.

N Engl J Med. 1998 Feb 12;338(7):409-15.

6.

Subcutaneous adjusted-dose unfractionated heparin vs fixed-dose low-molecular-weight heparin in the initial treatment of venous thromboembolism.

Prandoni P, Carnovali M, Marchiori A; Galilei Investigators.

Arch Intern Med. 2004 May 24;164(10):1077-83.

PMID:
15159264
7.

Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.

Koopman MM, Prandoni P, Piovella F, Ockelford PA, Brandjes DP, van der Meer J, Gallus AS, Simonneau G, Chesterman CH, Prins MH.

N Engl J Med. 1996 Mar 14;334(11):682-7. Erratum in: N Engl J Med 1997 Oct 23;337(17):1251.

8.
9.

Deep venous thrombosis and pulmonary embolism. Part 1. Initial treatment: usually a low-molecular-weight heparin.

[No authors listed]

Prescrire Int. 2013 Apr;22(137):99-101, 103-4. Review.

PMID:
23662321
10.
11.

Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease.

Merli G, Spiro TE, Olsson CG, Abildgaard U, Davidson BL, Eldor A, Elias D, Grigg A, Musset D, Rodgers GM, Trowbridge AA, Yusen RD, Zawilska K; Enoxaparin Clinical Trial Group.

Ann Intern Med. 2001 Feb 6;134(3):191-202.

PMID:
11177331
12.

The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group.

Schulman S, Granqvist S, Holmström M, Carlsson A, Lindmarker P, Nicol P, Eklund SG, Nordlander S, Lärfars G, Leijd B, Linder O, Loogna E.

N Engl J Med. 1997 Feb 6;336(6):393-8.

13.

Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism.

van Den Belt AG, Prins MH, Lensing AW, Castro AA, Clark OA, Atallah AN, Burihan E.

Cochrane Database Syst Rev. 2000;(2):CD001100. Review. Update in: Cochrane Database Syst Rev. 2004;(4):CD001100.

PMID:
10796593
14.

Venographic comparison of subcutaneous low-molecular weight heparin with oral anticoagulant therapy in the long-term treatment of deep venous thrombosis.

Gonzalez-Fajardo JA, Arreba E, Castrodeza J, Perez JL, Fernandez L, Agundez I, Mateo AM, Carrera S, Gutiérrez V, Vaquero C.

J Vasc Surg. 1999 Aug;30(2):283-92.

15.

A meta-analysis of thromboembolic prophylaxis following elective total hip arthroplasty.

Freedman KB, Brookenthal KR, Fitzgerald RH Jr, Williams S, Lonner JH.

J Bone Joint Surg Am. 2000 Jul;82-A(7):929-38.

PMID:
10901307
16.

Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis.

Prandoni P, Lensing AW, Büller HR, Carta M, Cogo A, Vigo M, Casara D, Ruol A, ten Cate JW.

Lancet. 1992 Feb 22;339(8791):441-5.

PMID:
1346817
17.

Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.

Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, Rickles FR, Julian JA, Haley S, Kovacs MJ, Gent M; Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators.

N Engl J Med. 2003 Jul 10;349(2):146-53.

18.

Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism.

Kearon C, Ginsberg JS, Julian JA, Douketis J, Solymoss S, Ockelford P, Jackson S, Turpie AG, MacKinnon B, Hirsh J, Gent M; Fixed-Dose Heparin (FIDO) Investigators.

JAMA. 2006 Aug 23;296(8):935-42.

PMID:
16926353
20.

Treatment of deep vein thrombosis in patients with pulmonary embolism: subgroup analysis on the efficacy and safety of certoparin vs. unfractionated heparin.

Riess H, Becker LK, Melzer N, Harenberg J.

Blood Coagul Fibrinolysis. 2014 Dec;25(8):838-44. doi: 10.1097/MBC.0000000000000166.

PMID:
25004024

Supplemental Content

Support Center